← All trials
NCT05852990
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2022
- Primary completion
- Dec 1, 2023
- Completion date
- Dec 12, 2023
- First posted
- May 10, 2023
- Last posted
- May 10, 2023
- Enrollment
- 28
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of MexicoLead sponsor
- Government of MexicoReponsible party - principal investigator
- Government of MexicoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.